Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 17:4:114.
doi: 10.3389/fphar.2013.00114. eCollection 2013.

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization

Maurizio Capuozzo  1 , Alessandro Ottaiano, Eduardo Nava, Valerio Scotti, Stefania Cascone, Adriano Vercellone, Claudia Cinque, Rosario V Iaffaioli
Affiliations

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization

Maurizio Capuozzo et al. Front Pharmacol. .
No abstract available

Keywords: HCV; boceprevir; pharmacoutilization; survey; telaprevir.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Asselah T. (2012). Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Best Pract. Res. Clin. Gastroenterol. 26, 455–462 10.1016/j.bpg.2012.09.003 - DOI - PubMed
    1. Esteban R., Buti M. (2012). Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. Best Pract. Res. Clin. Gastroenterol. 26, 445–453 10.1016/j.bpg.2012.09.001 - DOI - PubMed
    1. Manns M. P., Wedemeyer H., Cornberg M. (2006). Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350–1359 10.1136/gut.2005.076646 - DOI - PMC - PubMed
    1. Popescu C., Gliga S., Aramã V. (2012). Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals. Rom. J. Intern. Med. 50, 117–127 - PubMed
    1. Romano K. P., Ali A., Aydin C., Soumana D., Ozen A., Deveau L. M., et al. (2012). The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8:e1002832 10.1371/journal.ppat.1002832 - DOI - PMC - PubMed

LinkOut - more resources